CX vs IONS Comparison

Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.